TNFa-IL-17 bispecific antibodies

US10329346B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Johannes Auer · Schwaigen, DE
• Martin Bader · Penzberg, DE
• Jens Fischer · Penzberg, DE
• Stefan Lorenz · Penzberg, DE
• Joerg Moelleken · Penzberg, DE
• Stefan Seeber · Penzberg, DE

Key dates

• Filing date: Feb 1, 2016
• Grant date: Jun 25, 2019
• Expiry date: Jul 31, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Bispecific tetravalent antibodies against IL-17 and TNFa, useful in therapy, e.g. the treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions.